辛伐他汀对血脂异常绝经糖尿病女性骨密度及上肢骨折愈合的影响

目的探讨血脂代谢异常绝经后糖尿病女性应用辛伐他汀(20mg/d)进行降脂治疗时,对上肢骨折患者术后骨密度及骨折愈合的影响。方法随访86例上肢骨折的血脂代谢异常绝经后糖尿病女性患者,依据患者是否服用降脂药物辛伐他汀(20mg/d)治疗分为对照组和治疗组,比较两组患者在院期间及术后3月健侧桡骨远端骨密度及骨折愈合的差异。结果在院期间治疗组与对照组健侧桡骨远端1/3处骨密度相比差异无统计学意义(P0.05)。治疗3个月后,治疗组骨密度与治疗前相比差异无统计学意义(P0.05);对照组骨密度与治疗前相比差异无统计学意义(P0.05);治疗3个月后治疗组与对照组两组间骨密度差异无统计学意义(P0.05)。治疗组与对照组相比骨折愈合人数差异无统计学意义,降脂治疗剂量的辛伐他汀(20mg/d)没有体现出具有促进骨折愈合的作用。结论血脂代谢异常绝经后糖尿病骨折女性,在应用辛伐他汀(20mg/d)进行降脂治疗3个月期间,对桡骨远端骨密度及骨折愈合没有影响。     

绝经后女性骨质疏松合并骨折血清25羟维生素D水平研究

目的 探讨绝经后女性骨质疏松合并骨折血清25羟维生素D的水平.方法 选择2010年1月-2013年5月在解放军第309医院骨内科住院的86例患者,包括绝经后骨质疏松合并骨折患者42例,年龄(70.38±6.11)岁,不伴骨折绝经后骨质疏松患者44例,年龄(67.32±8.93)岁.采用美国Norland双光能X线骨密度检测仪对所有患者进行腰椎L2-L4和左侧股骨近端(包括Neck、Troch、Ward''s三角区)骨密度测量,并测定身高、体重、血谷丙转氨酶(ALT)、谷草转氨酶(AST)、肌酐(CRE)、尿素氮(BUN).采用酶联免疫吸附法测定两组患者血清25羟维生素D,比较两组25羟维生素D水平.结果 绝经后骨质疏松合并骨折组患者血清25羟维生素D(12.40±3.7) ng/ml,较绝经后非骨折骨质疏松患者(16.23 ±4.6)ng/ml低,差异具有统计学意义(P＜0.05);绝经后骨质疏松合并骨折组患者ALT(18.22±8.17) IU/L、AST(20.70±12.67) IU/L、CRE(56.76±11.81)umol/L、BUN(5.20±1.40) mmol/L与骨质疏松组ALT(21.32±12.16)IU/L、AST(22.16±8.36) IU/L、CRE(57.29±13.42) umol/L、BUN(5.2±1.8) mmol/L相比,差异无统计学意义(P＞0.05);绝经后骨质疏松合并骨折患者L2-4、Neck、Troch、Ward''s三角区的骨密度分别为(0.75 ±0.19) g/cm2、(0.61 ±0.18)g/cm2、(0.50±0.12) g/cm2、(0.40±0.14)g/cm2与对照组(0.81 ±0.33) g/cm2、(0.67 ±0.11)g/cm2、(0.52±0.10) g/cm2、(0.45±0.1)g/cm2相比较,差异没有统计学意义(P＞0.05).结论 绝经后骨质疏松合并骨折患者较未合并骨折骨质疏松维生素D缺乏更严重.     

辛伐他汀对桡骨远端骨折老年女性骨密度及骨折愈合的影响

目的探讨辛伐他汀对老年女性桡骨远端骨折骨密度及骨折愈合的影响。方法分析98名桡骨远端骨折老年女性术前及术后3个月健侧桡骨远端1/3处骨密度,依据术后是否口服辛伐他汀治疗其他内科疾患分为辛伐他汀治疗组(56例)及对照组(42例)。结果治疗前辛伐他汀组与对照组健侧桡骨远端1/3处骨密度差异无统计学意义(P0.05)。治疗3个月后辛伐他汀组健侧桡骨远端1/3处骨密度与治疗前骨密度相比差异具有统计学意义(P0.05);对照组健侧桡骨远端1/3处骨密度均值增高,与初始时差异无统计学意义(P0.05)。治疗3个月后辛伐他汀组与对照组两组间骨密度差异无统计学意义(P0.05)。通过卡方检验分析发现辛伐他汀组与对照组相比骨折愈合数存在统计学差异,辛伐他汀可以促进骨折愈合;分析两组间治疗前后骨质正常、骨量减少、骨质疏松数之间差异无统计学意义,辛伐他汀不影响骨质疏松患病率。结论桡骨远端骨折老年女性应用辛伐他汀(20 mg/d)可以改善桡骨远端骨密度、促进骨折愈合,但不影响骨质疏松患病率。     

最大限度雄激素阻断治疗前列腺癌对患者骨密度的影响

目的:探讨最大限度雄激素阻断(MAB)治疗对前列腺癌患者骨密度的影响。方法:对40例因前列腺癌行MAB治疗的患者进行调查,治疗时间7～12个月,分别于治疗前后检测血清前列腺特异性抗原(PSA)、睾酮及血钙、血磷、24 h尿钙、尿磷、碱性磷酸酶、甲状旁腺激素、血常规及肝肾功能,双能X线吸收法测定腰椎、股骨颈骨密度,并进行疼痛评分,比较MAB治疗前后各项指标差异。结果:前列腺癌患者治疗前5例(12.5%)腰椎骨量减少,8例(20.0%)腰椎骨质疏松;13例(32.5%)左股骨颈骨量减少,15例(37.5%)左股骨颈骨质疏松。MAB治疗前患者血清PSA为(52.9±69.9)μg/L,睾酮为(18.9±6.5)nmol/L,治疗后PSA为(1.5±1.6)μg/L,睾酮为(1.9±1.3)nmol/L,与治疗前比较均显著下降(P<0.05)。治疗前血钙为(2.5±0.2)mmol/L,血磷为(1.2±0.2)mmol/L,尿钙为(3.1±1.4)mmol/L,尿磷为(11.5±8.1)mmol/L,治疗后血钙为(2.5±0.1)mmol/L,血磷为(1.2±0.1)mmol/L,尿钙为(2.8±1.2)mmol/L,尿磷为(9.9±4.0)mmol/L,两者比较差异均无统计学意义(P>0.05)。治疗前后碱性磷酸酶、甲状旁腺激素、血常规、肝肾功能差异均无统计学意义(P>0.05)。治疗前腰椎和股骨颈骨密度分别为(1.1±0.1)g/cm2和(0.8±0.2)g/cm2,疼痛评分为(0.6±0.2)分,治疗后腰椎和股骨颈骨密度分别为(1.1±0.2)g/cm2和(0.8±0.1)g/cm2,疼痛评分为(0.7±0.1)分,与治疗前比较差异均无统计学意义(P>0.05)。结论:7～12个月MAB治疗对前列腺癌患者骨密度无明显影响,安全有效,但治疗前应注意监测患者骨密度。     

沈阳市2697名健康体检者超声跟骨骨密度调查分析

目的 了解沈阳地区健康男、女的骨密度情况。方法 回顾性分析2008~2010年中国医科大学附属盛京医院体检中心体检的1216名女性和1481名男性沈阳市健康体检者的骨密度，检测方法为定量超声跟骨骨密度测定。结果 女性平均T值-1.216±0. 960，男性平均T值-0.750±1. 028,二者差异显著；女性骨质疏松93例，占7.65%.，骨量减少663例，占52. 56%;男性骨质疏松37例，占 2.5%，骨量减少616例，占41.59%_。结论 女性各年龄段T值均低于男性，随着年龄增加，男女T值 均逐渐下降，进入围绝经期后女性T值下降更为迅速，定量超声跟骨骨密度测定可以作为骨量减少及骨质疏松的筛查手段。     

新疆乌鲁木齐市某社区维吾尔族女性跟骨骨密度与代谢综合征相关性分析

目的探索代谢综合征(MS)与不同年龄及代谢状态下维吾尔族女性定量骨超声检测跟骨骨密度(T值)与其之间的相关性。方法横断面研究,对象为新疆乌鲁木齐市二道桥某社区常住维族女性。按年龄分组,观察不同年龄段维族女性骨量的变化。按中华医学会糖尿病分会(CDS)[1]诊断MS的诊断标准,将549名女性分为高血压组136例,血压正常组413例;糖尿病组103例,血糖正常组446例;单纯肥胖或超重组290例,体重正常组259例;血脂紊乱组157例,血脂正常组392例;MS组86例,非MS组463例。根据既往史是否绝经分为未绝经组339例,绝经组182例;并用线性回归分析,研究跟骨骨密度的独立影响因素。结果高血压、糖代谢异常、MS组骨量T值均低于其代谢正常组,差异有统计学意义(均P0.05);高血压、糖代谢异常、超重或肥胖、MS组骨量减少、骨质疏松的患病率均高于其代谢正常组,差异有统计学意义(均P0.05);按年龄分组,不同组间T值不完全相同,随年龄增长,骨量减少的患病率升高,差异有统计学意义(P0.05);按是否合并绝经分组,绝经组骨量减少、骨质疏松的患病率明显升高,差异有统计学意义(P0.05)。结论 MS作为多种代谢异常的症候群,骨量减少的患病率高,是骨质疏松发生的高风险人群。绝经是女性骨量减少的独立危险因素。     

甘肃省兰州地区中老年女性骨密度现状调查及危险因素分析

目的调查研究甘肃省兰州地区中老年女性的骨密度情况,并分析体重指数与骨质疏松的相关性。方法选取2019年5月1日至2019年10月30日期间于甘肃省妇幼保健院行健康体检的女性。详细记录其年龄、绝经状态、身高及体重,采用双能X线吸收骨密度仪进行检测。结果共纳入2 078名研究对象。其中绝经前组204名,占9.82%,平均年龄(41.10±3.19)岁;围绝经期组443名,占21.32%,平均年龄(49.29±2.18)岁;绝经后组1 431名,占68.86%,平均年龄(56.25±7.59)岁。围绝经期组及绝经后组平均绝经年龄分别为(50.43±1.30)岁、(48.42±3.06)岁。三组平均身高、体重及体重指数分别为(1.59±0.05) m、(59.58±7.78) kg及(23.71±3.11) kg/m2。左侧股骨颈的平均骨密度分别为:绝经前组(0.85±0.14) g/cm2、围绝经期组(0.91±0.15) g/cm2、绝经后组(0.82±0.12) g/cm2;左侧全部髋关节的平均骨密度分别为:绝经前组(0.99±0.16)g/cm2、围绝经期组(0.97±0.17) g/cm2、绝经后组(0.88±0.13) g/cm2。腰1～4全部椎体的平均骨密度分别为:绝经前组(1.13±0.22) g/cm2、围绝经期组(1.10±0.20) g/cm2、绝经后组(0.97±0.15) g/cm2。所有绝经前女性的骨密度均正常;围绝经期女性中,正常骨密度占45.15%,骨量减少占32.28%,骨质疏松占22.57%;绝经后女性中,正常骨密度占19.57%,骨量减少占33.54%,骨质疏松占46.89%。Spearman等级相关分析结果示BMI与骨质疏松的发病率呈正向显著相关。结论甘肃省兰州地区中老年女性的骨质疏松发病率随年龄的增长而明显增高,尤其是绝经后及肥胖者,定期监测骨密度成为其不可或缺的体检项目。     

长期强的松治疗对绝经前SLE患者骨密度的影响

目的探讨长期强的松治疗对绝经前系统性红斑狼疮(SLE)患者骨密度的影响。方法142例SLE患者均为绝经前女性,年龄12~40岁(平均29·5岁)。正常对照78例女性,年龄15~39岁(平均28·9岁),排除影响骨代谢的各种急慢性疾病。应用HOLOGIC QDR4500双能量X线骨密度仪检测腰椎和股骨近端的骨密度值,测定血清雌二醇、雌三醇。结果①绝经前SLE患者骨量减少、骨质疏松发生率分别为42·96%、14·79%,均显著高于正常对照组(P值均<0·01);②骨质疏松和骨量减少患者服用强的松的时间、总剂量均显著高于骨量正常患者(P值均<0·01);③绝经前患者雌二醇与正常对照无显著差异,而雌三醇明显升高(P<0·01)。结论①长期服用强的松的绝经前SLE患者骨量减少和骨质疏松发生率均显著增高;②SLE患者骨量减少和骨质疏松的发生与使用强的松的时间和总剂量有关;③绝经前SLE患者雌三醇产生增多,可能对骨密度具有保护作用。     

绝经后妇女血维生素B12、叶酸水平与骨密度相关性的初步研究

目的探讨绝经后妇女血维生素B12、叶酸水平与骨密度的相关性。方法应用双能X线骨密度仪测定受试者腰椎及股骨骨密度,按1994年WHO标准将其分为3组,即骨质疏松组、骨量减少组及骨量正常组;采取空腹静脉血进行维生素B12、叶酸的集中检测;并分别进行维生素B12、叶酸与不同部位骨密度的相关性分析。结果①骨质疏松组的血维生素B12的水平(512.55±209.85)pg/ml,低于骨量减少组(551.29±237.71)pg/ml和骨量正常组(565.71±189.03)pg/ml。②骨质疏松组的血叶酸的水平(11.27±6.04)pg/ml,低于骨量减少组(13.18±6.14)pg/ml和骨量正常组(11.9±3.73)pg/ml。③绝经后妇女血维生素B12的水平与全髋BMD呈正相关(r=0.25,P<0.01),与股骨颈BMD呈正相关(r=0.212,P<0.05),与股骨干BMD呈正相关(r=0.257,P<0.01),与股骨大转子BMD呈正相关(r=0.239,P<0.05);血维生素B12的水平与L1~L4BMD无相关性(r=0.141,P>0.05)。④绝经后妇女血叶酸的水平与全髋BMD、股骨颈BMD、股骨干BMD、股骨大转子BMD和L1~L4BMD均无相关(r分别为0.005,0.021,0.017,-0.021和0.078,P>0.05)。结论绝经后妇女血维生素B12的水平的缺乏可能是骨质疏松发生的一个重要风险因素,叶酸的缺乏并非骨质疏松发生的风险因素。     

绝经后肥胖女性骨密度与血管内皮功能的关系研究

目的 探讨绝经后肥胖女性中骨密度(BMD)与血管内皮功能的相关性.方法 选择自然绝经1～5年的单纯肥胖者(体重指数≥25kg/m2),年龄40～55岁,按照双能X线检测结果选择正常骨量组39例,骨量减少组37例和骨质疏松组19例.所有受试者测定体脂、BMD、骨矿含量(BMC)和血管内皮功能,包括血流介导的内皮依赖性血管舒张(EDD)和硝酸甘油介导的非内皮依赖性血管舒张.结果 骨质疏松组平均年龄和平均绝经时间显著高于正常骨量组和骨量减少组(P<0.05或P<0.01).骨质疏松组及骨量减少组BMD和BMC均显著低于正常骨量组(P<0.05或P<0.01).骨质疏松组EDD显著低于正常体重组和骨量减少组(分别为5.45±2.99、7.76±3.70和7.32±3.41,均P<0.05).相关分析显示各部位的BMD、BMC均与EDD相关(P<0.05和P<0.01).结论 肥胖女性绝经后骨质疏松与血管内皮功能异常有关,对绝经后肥胖女性低骨量人群干预治疗可能有助于防治动脉硬化及心血管疾病.     

重庆地区围绝经期与绝经后妇女骨密度及身体成分相关指标分析

目的 调查重庆地区围绝经期与绝经后妇女(5~10年）骨密度及相关身体成分指标,分析身体成分指标与骨密度的关系,为本地区骨质疏松的防治提供线索。方法 ①选取2017年于本院进行健康体检年龄≥45岁的妇女956名(排除相关原发疾病）,其中围绝经期510名,绝经后446名,并分别记录身高、体重,计算出体质量指数(body mass index, BMI）;②使用美国GE公司双能X线骨密度仪测定受试者腰椎1~4、左侧股骨颈、大转子、股骨干、全髋的骨密度以及全身脂肪、肌肉含量与骨矿含量。结果 一般情况分析发现,重庆地区围绝经期妇女身高明显高于绝经后妇女［分别为(156.81 ± 5.27) cm、(153.32 ±5.51) cm］,而体质量指数无明显差异。 绝经后妇女肌肉含量(37.91 ± 6.42) kg、脂肪含量(17.84 ± 2.16) kg、骨矿含量(1.58±0.41) kg均较围绝经期妇女 [(37.88 ± 6.15) kg、(19.21 ± 2.07) kg、(1.75±0.20) kg ]降低。绝经后妇女诊断骨质疏松与低骨量的比例分别为28.92%、41.03%,高于围绝经期妇女低骨量的发生率(28.63%)。围绝经期妇女腰椎1~4和左侧股骨颈、大转子、股骨干及全髋骨密度 (bone mineral density, BMD)明显高于绝经后妇女［分别是(1.0 959 ± 0.1 603) g/m2和(0.8 410 ± 0.1 606) g/m2,(0.8 178 ± 0.1 577) g/m2和(0.7 872 ± 0.1 585) g/m2,(0.6 946 ± 0.1 252) g/m2和(0.6 728±0.1 274) g/m2,(1.0 329 ± 0.1 712) g/m2和(1.0 030±0.1 737) g/m2,(0.8 773 ± 0.1 448) g/m2和(0.8 495 ± 0.1 478) g/m2］。结论 绝经后妇女髋部、腰椎等部位BMD均较围绝经期妇女明显降低;骨质疏松及低骨量的发生率随年龄增加显著升高;和围绝经期妇女相比,绝经后妇女全身脂肪含量偏低;BMD与全身肌肉含量呈正相关性。     

Osteoporosis and Coronary Atherosclerosis in Asymptomatic Postmenopausal Women

Estrogen deficiency is a risk factor for osteoporosis and coronary artery disease. Osteoporosis can be evaluated by measuring bone mineral density (BMD). Coronary atherosclerotic burden can be evaluated by measuring coronary calcium using electron beam computed tomography (EBT) of the heart. We compared coronary calcium scores in 45 asymptomatic postmenopausal women with normal and low BMD. BMD of the lumbar spine and proximal femur was measured by dual X-ray absorptiometry (DXA), and coronary calcium was measured quantitatively by EBT. Women were divided into control, osteopenia, and osteoporosis groups based on the T score of the lumbar spine. Women were similar in age, years since menopause, height, weight, and body mass index (BMI). BMD ± SD (g/cm²) of L1–L4 was 0.96 ± 0.11, 0.83 ± 0.03, and 0.73 ± 0.05, in control, osteopenia, and osteoporosis group, respectively. The total coronary calcium score ± SD (relative units) was 41.9 ± 83.1, 115.1 ± 181.9, and 221.7 ± 355.4 for control, osteopenia, and osteoporosis group, respectively; the score was significantly higher in the osteoporosis than in the control group. This study provides initial data suggesting that women with osteoporosis may have a higher risk of developing coronary atherosclerosis.     

The association between serum thyroid-stimulating hormone in its reference range and bone status in postmenopausal American women

Evidence suggests that hyperthyroidism adversely affects bone, but the condition is rare and probably contributes little to postmenopausal osteoporosis. Subclinical hyperthyroidism, which can result from treatment with L-thyroxine, is more common, but its relationship to osteoporosis and fracture is uncertain. A recent study of healthy, postmenopausal Koreans with no history of thyroid disease reported associations between both below-normal and low-normal circulating thyroid-stimulating hormone (TSH) levels and osteoporosis. These findings raise the hypothesis that variation in thyroid function, or TSH itself, affects bone in normal women. In the present research, we used data collected in the third U.S. National Health and Nutrition Examination Survey to examine associations between TSH, as it varies over its reference range, and bone status in healthy, postmenopausal American women. In some analyses, we used osteoporosis and osteopenia defined according to World Health Organization guidelines as the outcome variable. In others, we used bone mineral density (BMD) as a continuum. After adjustment for age, race/ethnicity, body mass index, serum T(4), estrogen replacement therapy, smoking, and physical activity level, the odds ratios (95% CI) relating TSH between 0.39 and 1.8 mIU/L (the median of the reference range) versus TSH between 1.8 and 4.5 to osteoporosis and osteopenia were 3.4 (95% CI, 1.3-9.2) and 2.2 (1.2-3.8), respectively. Furthermore, BMD increased significantly as TSH increased over its reference range in both black and white women. After multivariate adjustment, least-square mean BMD for non-Hispanic white women in the bottom serum TSH quintile category was 0.79 g/cm(2) (95% CI, 0.76-0.82), as compared to 0.83 g/cm(2) (95% CI, 0.8-0.85) for those in the top quintile category. Least-square mean BMD (95% CI) for non-Hispanic black women in the bottom serum TSH quintile category was 0.85 g/cm(2) (95% CI, 0.81-0.89). For non-Hispanic black women in the top quintile category, least-square mean BMD was 0.94 g/cm(2) (95% CI, 0.88-0.99). These results may reflect the existence of clinically significant thyroid hyperfunction in women with serum TSH in the reference range. Alternatively, TSH itself may play a role in the preservation of bone after menopause.     

Reference Data and Predictive Diagnostic Models for Calcaneus Bone Mineral Density Measured with Single-Energy X-ray Absorptiometry in 7428 Chinese

Calcaneus bone mineral density (BMD) of 7428 Chinese (4126 women, 3302 men; aged 22–94 years) was measured using single-energy X-ray absorptiometry (SXA). A reference range of calcaneus BMD values for healthy Chinese men and women was established and the usefulness of this method for screening and diagnosis in osteoporosis was evaluated. The peak BMD occurred at 20–24 years old and peak BMD in women was significantly lower than in men. BMD loss in the calcaneus started at the age of 35 years for women, and at 63 years in men. BMD loss rate was 1.2%/year for women and 0.56 %/year for men after 50 years. The young normal reference for calcaneus BMD was 442.1±69.6 mg/cm² for men and 388.3±61.7 mg/cm² for women calculated from the mean BMD value of subjects whose age ranged from 20 to 49 years. The accumulated BMD loss in the calcaneus is similar to that of Ward’s triangle. Multiple linear regression showed that both age and weight were important factors. The incidence of osteoporosis in older men and women (≥60 years) is 6.6% and 32.1% respectively. We conclude that calcaneus BMD measurement is useful and sensitive for the screening and diagnosis of osteoporosis. A predictive diagnostic model for osteoporosis based on the calcaneus was constructed using multiple linear regression and the WHO criteria for diagnosing osteoporosis can be applied to calcaneus BMD. Received: 16 August 2000 / Accepted: 20 March 2001     

Lower vitamin E serum levels are associated with osteoporosis in early postmenopausal women: a cross-sectional study

The aim of this study was to evaluate the relationship between vitamin E status and osteoporosis in early postmenopausal women. Anthropometric data, osteoporosis risk factors, vitamin E serum levels, bone mineral density (BMD) and other serum parameters which may influence bone mineral density in postmenopausal women were analyzed in a cross-sectional study. The association between osteoporosis and age, age of menopause, body mass index, osteocalcin, calcium, vitamin D, vitamin E (measured as 25 hydroxyvitamin D and as α-tocopherol:lipids ratio, respectively), bone alkaline phosphatase, smoking status, leisure physical activity and alcohol intake were modeled by a multivariate logistic regression and multi-linear regression analysis in 232 early postmenopausal women. A lower vitamin E:lipid ratio was associated with osteoporosis in multivariate logistic regression. In a multivariate linear model with BMD of the lumbar spine as a dependent variable, the vitamin E:lipid ratio was clearly related with BMD of the lumbar spine (F ratio = 6.30, p = 0.002). BMD of the lumbar spine was significantly higher in the highest tertile of the vitamin E:lipid ratio than in the lowest tertile. The mean vitamin E:lipid ratio was significantly lower in osteoporotic postmenopausal women (T score ≤?2.5) (3.0 ± 0.6 μmol/mmol) than normal (neither osteoporotic nor osteopenic) postmenopausal women (T score >?1) (3.5 ± 0.7 μmol/mmol) using multivariable-adjusted BMD. These findings highlight that vitamin E may increase BMD in healthy postmenopausal women.     

女性正常范围促甲状腺激素水平与骨代谢的相关性研究

目的探讨正常范围内促甲状腺激素(Thyroid Stimulating Hormone,TSH)水平对女性骨代谢指标的影响。方法选取896名甲状腺功能正常的女性,根据TSH水平进行三分位数法分组,未绝经组:T1组(0.27-2.00 mIU/L)、T2组(2.01-2.8mIU/L)及T3组(2.81-4.2 mIU/L);绝经组:T1组(0.27-2.01 mIU/L)、T2组(2.02-3.23 mIU/L)及T3组(3.24-4.2mIU/L)。比较各组间血钙、血磷、25(OH)vitD、腰围、BMI、BMD水平之间差异。spearman相关性分析TSH水平与骨量等级之间的相关性。以BMD作为因变量,对其分层后进行二元Logistic回归分析不同TSH水平对女性骨质疏松发生的影响。结果 (1)绝经期组T1组和T2组的左前臂BMD均明显低于T3组(P0.05),T1组和T2组右跟骨BMD均明显低于T3组(均P0.05);未绝经组3组间各指标无明显差异。(2)绝经组分层后的TSH水平与右跟骨、左前臂骨量等级呈负相关(r=-0.228,P0.05;r=-0.145,P0.05)。未绝经组分层后的TSH水平与右跟骨、左前臂骨量等级无相关性。(3)二元Logistic回归分析:以分组后的右跟骨BMD作为因变量,校正性别、年龄、BMI、腰围、血钙、血磷、25(OH)vitD后,绝经后女性T1组能够增加骨质疏松的风险(OR=2.278,95%CI 1.011～5.132,P0.05)。结论绝经后女性正常范围低水平TSH的骨密度更低,患骨质疏松的风险增高。     

Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women.

To study effects of statins on human bone, 82 postmenopausal women were randomized to 1-year treatment with simvastatin 40 mg/day or placebo. The study showed no effect of simvastatin on biochemical bone markers or on BMD at the hip or spine. Thus, our results do not support a general beneficial effect of simvastatin on bone. INTRODUCTION: Statins have been reported to cause bone anabolic as well as antiresorptive effects, and therefore statins have been suggested as potential agents in treatment of osteoporosis. MATERIALS AND METHODS: In a double-blinded design, 82 healthy postmenopausal women with osteopenia were randomized to 1-year simvastatin treatment 40 mg/day or placebo. BMD and plasma levels of cholesterol, parathyroid hormone (PTH), and biochemical bone markers were measured at baseline, after 1 year of treatment (week 52), and 26 weeks after withdrawal of treatment (week 78). Calcium supplements (400 mg/day) were administrated during the entire 1.5-year study period. RESULTS: Seventy-eight women completed the 1-year treatment. After 1 year, simvastatin but not placebo caused reduced plasma cholesterol (-27% versus +1%, p < 0.001) and low-density lipoprotein (LDL) levels (-43% versus +1%, p < 0.001). After withdrawal of treatment, cholesterol and LDL levels returned to baseline levels and no longer differed from the placebo group. However, plasma levels of PTH and biochemical bone markers did not differ between groups at week 52 or 78. Compared with placebo, simvastatin caused no changes in BMD at the lumbar spine, total hip, femoral neck, or whole body at week 52 or 78. However, a significant increase in BMD was found in response to simvastatin at the forearm. Within the simvastatin group, changes in cholesterol levels did not correlate to BMD changes at any site. CONCLUSIONS: Our results do not support a general beneficial effect of simvastatin on bone.